Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772018 · ClinicalTrials.gov registry record
Quality of Life and Symptom Management in Patients With Bladder Cancer
A clinical trial of Bladder Cancer, sponsored by David Latini.
- Completed
- Registry status
- 28
- Enrollment target
- 2
- Study locations
NCT00772018: Completed study of Bladder Cancer, sponsored by David Latini.
NCT00772018 is a study of Bladder Cancer that has completed, run by David Latini. The registered enrollment target is 28 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00772018, a study of Bladder Cancer, has completed, sponsored by David Latini.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Learning about quality of life and symptom management in patients with bladder cancer may help doctors learn about the effects of treatment and plan the best treatment. PURPOSE: This clinical trial is studying of quality of life and symptom management in patients with bladder cancer.
Primary Outcome
Study is a retrospective qualitative study of nonmuscle-invasive bladder cancer patients using a semi-structured interview protocol.
Conditions Studied
Study Locations (2)
Texas
- Dan L. Duncan Cancer Center at Baylor College of Medicine - Houston
- Veterans Affairs Medical Center - Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-09 |
What the finished NCT00772018 record still lists
NCT00772018 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00772018 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00772018 about?
NCT00772018 is a clinical study titled "Quality of Life and Symptom Management in Patients With Bladder Cancer". RATIONALE: Learning about quality of life and symptom management in patients with bladder cancer may help doctors learn about the effects of treatment and plan the best treatment. PURPOSE: This clinical trial is studying of quality of life and symptom management in patients with bladder cancer.
What is the current status of trial NCT00772018?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2008-05. Estimated completion is 2010-09.
What conditions does trial NCT00772018 study?
This clinical trial studies the following conditions: Bladder Cancer.
Who is sponsoring clinical trial NCT00772018?
This trial is sponsored by David Latini, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00772018 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00772018's enrollment target sits among peer trials
28 140th of 175 higher than 36 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia